Reduction of the remaining residual cardiovascular risk is a clinical unmet need currently being addressed through a combination of further reduction of plasma concentrations of low-density lipoproteins (LDLs) and increasing plasma concentrations of high-density lipoproteins (HDLs). This brief review sets out the so-called HDL hypothesis and summarises the clinical results of the family of drugs, which function to raise plasma HDL concentration through inhibition of cholesteryl ester transfer proteins (CEPT).
Christopher Huggins - Cardiovascular & Cell Sciences, St George’s, University of London, UK
Nicoletta Charolidi - Cardiovascular & Cell Sciences, St George’s, University of London, UK
Gillian W Cockerill - Cardiovascular & Cell Sciences, St George’s, University of London, UK
